BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 2016;7:22257-70. [PMID: 26989027 DOI: 10.18632/oncotarget.8076] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
Number Citing Articles
1 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
2 Wiesweg M, Reis H, Köster T, Goetz M, Worm K, Herold T, Paul A, Dechêne A, Schumacher B, Markus P, Virchow I, Kostbade K, Wolf N, Zaun G, Metzenmacher M, Schmid KW, Schuler M, Kasper S. Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2018;17:e331-52. [PMID: 29526493 DOI: 10.1016/j.clcc.2018.02.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
3 Chiang S, Huang HH, Tsai W, Chin-ming Tan B, Yang C, Huang P, Yi-feng Chang I, Lin J, Lu P, Chin E, Liu Y, Yu J, Chiang J, Hung H, You J, Liu H. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal 2021. [DOI: 10.1016/j.bj.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Eurboonyanun K, Lahoud RM, Kordbacheh H, Pourvaziri A, Promsorn J, Chadbunchachai P, O'Shea A, Atre ID, Harisinghani M. Imaging predictors of BRAF mutation in colorectal cancer. Abdom Radiol (NY) 2020;45:2336-44. [PMID: 32193591 DOI: 10.1007/s00261-020-02484-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Akbarzadeh Khiavi M, Safary A, Barar J, Ajoolabady A, Somi MH, Omidi Y. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cell Mol Life Sci 2020;77:997-1019. [DOI: 10.1007/s00018-019-03305-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics 2019;13:33-51. [PMID: 31118560 DOI: 10.2147/BTT.S166310] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
7 Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, Lisgo AJ, Little L, Vercauteren E, Steiniche T, Meyer T, Simpson J. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 2018;71:336-43. [PMID: 28899979 DOI: 10.1136/jclinpath-2017-204629] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
8 Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, Zhang J. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget 2017;8:23436-47. [PMID: 28423582 DOI: 10.18632/oncotarget.15584] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
9 Yosef HK, Frick T, Hammoud MK, Maghnouj A, Hahn S, Gerwert K, El-mashtoly SF. Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst 2018;143:6069-78. [DOI: 10.1039/c8an02029a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
10 da Silva WC, de Araujo VE, Lima EMEA, Dos Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B, Kurdi A, Cherchiglia ML, Andrade EIG. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs 2018;32:585-606. [PMID: 30499082 DOI: 10.1007/s40259-018-0322-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
11 Carter R, Cheraghchi-Bashi A, Westhorpe A, Yu S, Shanneik Y, Seraia E, Ouaret D, Inoue Y, Koch C, Wilding J, Ebner D, Ryan AJ, Buffa FM, Sharma RA. Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer. Cancer Biol Med 2019;16:234-46. [PMID: 31516745 DOI: 10.20892/j.issn.2095-3941.2018.0284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li G, Pavlick D, Chung JH, Bauer T, Tan BA, Peguero J, Ward P, Kallab A, Bufill J, Hoffman A, Sadiq A, Edenfield J, He J, Cooke M, Hughes J, Forcier B, Nahas M, Stephens P, Ali SM, Schrock AB, Ross JS, Miller VA, Gregg JP. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. J Gastrointest Oncol 2019;10:831-40. [PMID: 31602320 DOI: 10.21037/jgo.2019.05.05] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
13 Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res 2021;164:105374. [PMID: 33348026 DOI: 10.1016/j.phrs.2020.105374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bolhuis K, van 't Erve I, Mijnals C, Delis-Van Diemen PM, Huiskens J, Komurcu A, Lopez-Yurda M, van den Broek D, Swijnenburg RJ, Meijer GA, Punt CJA, Fijneman RJA. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. EBioMedicine 2021;70:103498. [PMID: 34333237 DOI: 10.1016/j.ebiom.2021.103498] [Reference Citation Analysis]
15 Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther 2016;9:7355-65. [PMID: 27980425 DOI: 10.2147/OTT.S99807] [Cited by in Crossref: 83] [Cited by in F6Publishing: 41] [Article Influence: 13.8] [Reference Citation Analysis]
16 Huang L, Wen C, Yang X, Lou Q, Wang X, Che J, Chen J, Yang Z, Wu X, Huang M, Lan P, Wang L, Iwamoto A, Wang J, Liu H. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. Cell Death Dis 2018;9:271. [PMID: 29449544 DOI: 10.1038/s41419-018-0320-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
17 Farooqi AS, Hong JY, Cao J, Lu X, Price IR, Zhao Q, Kosciuk T, Yang M, Bai JJ, Lin H. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model. J Med Chem 2019;62:4131-41. [PMID: 30986062 DOI: 10.1021/acs.jmedchem.9b00191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
18 Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep. 2018;23:172-180.e3. [PMID: 29617658 DOI: 10.1016/j.celrep.2018.03.046] [Cited by in Crossref: 60] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
19 Li C, E C, Zhou Y, Yu W. Candidate genes and potential mechanisms for chemoradiotherapy sensitivity in locally advanced rectal cancer. Oncol Lett 2019;17:4494-504. [PMID: 30944639 DOI: 10.3892/ol.2019.10087] [Reference Citation Analysis]
20 Zhai Z, Yu X, Yang B, Zhang Y, Zhang L, Li X, Sun H. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol 2017;64:107-15. [PMID: 27578007 DOI: 10.1016/j.semcdb.2016.08.033] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
21 van 't Erve I, Greuter MJE, Bolhuis K, Vessies DCL, Leal A, Vink GR, van den Broek D, Velculescu VE, Punt CJA, Meijer GA, Coupé VMH, Fijneman RJA. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. J Mol Diagn 2020;22:1430-7. [PMID: 32961317 DOI: 10.1016/j.jmoldx.2020.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zilberg C, Lee MW, Kraitsek S, Ashford B, Ranson M, Shannon K, Iyer NG, Ch'ng S, Low TH, Palme C, Clark J, Gupta R, Yu B. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies? J Clin Pathol 2020;73:17-22. [PMID: 31300530 DOI: 10.1136/jclinpath-2019-206038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Mohamed A, Twardy B, AbdAllah N, Akhras A, Ismail H, Zordok M, Schrapp K, Attumi T, Tesfaye A, El-Rayes B. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. J Gastrointest Cancer 2019;50:269-75. [PMID: 29388061 DOI: 10.1007/s12029-018-0062-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cornejo KM, Cosar EF, Paner GP, Yang P, Tomaszewicz K, Meng X, Mehta V, Sirintrapun SJ, Barkan GA, Hutchinson L. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. Int J Surg Pathol 2020;28:51-9. [PMID: 31496327 DOI: 10.1177/1066896919872535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Wang C, Divito SJ, Chung W, Hung S. Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. Immunology and Allergy Clinics of North America 2022. [DOI: 10.1016/j.iac.2022.01.002] [Reference Citation Analysis]
26 Lombardi A, Russo M, Luce A, Morgillo F, Tirino V, Misso G, Martinelli E, Troiani T, Desiderio V, Papaccio G, Iovino F, Argenziano G, Moscarella E, Sperlongano P, Galizia G, Addeo R, Necas A, Necasova A, Ciardiello F, Ronchi A, Caraglia M, Grimaldi A. Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. High Throughput 2020;9:E4. [PMID: 32054005 DOI: 10.3390/ht9010004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, Chen VW. KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. J Natl Compr Canc Netw 2017;15:1484-93. [PMID: 29223986 DOI: 10.6004/jnccn.2017.7011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
28 Fior R, Póvoa V, Mendes RV, Carvalho T, Gomes A, Figueiredo N, Ferreira MG. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc Natl Acad Sci U S A 2017;114:E8234-43. [PMID: 28835536 DOI: 10.1073/pnas.1618389114] [Cited by in Crossref: 122] [Cited by in F6Publishing: 113] [Article Influence: 24.4] [Reference Citation Analysis]
29 Makino Y, Arakawa Y, Yoshioka E, Shofuda T, Minamiguchi S, Kawauchi T, Tanji M, Kanematsu D, Nonaka M, Okita Y, Kodama Y, Mano M, Hirose T, Mineharu Y, Miyamoto S, Kanemura Y. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer 2021;21:1025. [PMID: 34525976 DOI: 10.1186/s12885-021-08733-4] [Reference Citation Analysis]
30 Huang KC, Chiang SF, Ke TW, Chen WT, Chen TW, Chao KC. The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). Cancer Genomics Proteomics 2020;17:291-9. [PMID: 32345670 DOI: 10.21873/cgp.20189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. Future Oncol 2020;16:161-73. [PMID: 32027186 DOI: 10.2217/fon-2019-0748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget 2016;7:82185-99. [PMID: 27636997 DOI: 10.18632/oncotarget.11985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One 2020;15:e0227261. [PMID: 31914141 DOI: 10.1371/journal.pone.0227261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Li X, Chung ACK, Li S, Wu L, Xu J, Yu J, Wong C, Cai Z. LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer. Oncotarget 2017;8:101333-44. [PMID: 29254168 DOI: 10.18632/oncotarget.21093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Dou J, Wang Z, Ma L, Peng B, Mao K, Li C, Su M, Zhou C, Peng G. Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. Oncotarget 2018;9:20089-102. [PMID: 29732005 DOI: 10.18632/oncotarget.24015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
36 Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int J Mol Sci 2017;18:E2229. [PMID: 29064420 DOI: 10.3390/ijms18102229] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
37 Tsai HL, Tai CJ, Huang CW, Chang FR, Wang JY. Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Mar Drugs 2017;15:E122. [PMID: 28430159 DOI: 10.3390/md15040122] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
38 Ukmar G, Melloni GEM, Raddrizzani L, Rossi P, Di Bella S, Pirchio MR, Vescovi M, Leone A, Callari M, Cesarini M, Somaschini A, Della Vedova G, Daidone MG, Pettenella M, Isacchi A, Bosotti R. PATRI, a Genomics Data Integration Tool for Biomarker Discovery. Biomed Res Int 2018;2018:2012078. [PMID: 30065933 DOI: 10.1155/2018/2012078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
39 Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer. Oncol Lett 2021;21:41. [PMID: 33262833 DOI: 10.3892/ol.2020.12302] [Reference Citation Analysis]
40 Qiu C, Xie S, Cheng N, Lin Q, Shen G, Xiang Z, Huang T, Zhang X, Duan J, Wei L, Zheng Z. Case Report: Cetuximab in Combination With Chemotherapy for the Treatment of Multifocal Hepatic Metastases From Colorectal Cancer Guided by Genetic Tests. Front Oncol 2021;11:612171. [PMID: 33889542 DOI: 10.3389/fonc.2021.612171] [Reference Citation Analysis]
41 Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 2018;37:3183-99. [DOI: 10.1038/s41388-018-0171-x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 112] [Article Influence: 29.8] [Reference Citation Analysis]
42 Wang G, He Y, Sun Y, Wang W, Qian X, Yu X, Pan Y. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clin Transl Oncol 2020;22:813-22. [PMID: 31587152 DOI: 10.1007/s12094-019-02213-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
43 Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK, Tu YX. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling. J Exp Clin Cancer Res 2018;37:151. [PMID: 30005681 DOI: 10.1186/s13046-018-0836-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
44 Zou S, Li W, Wang W, Li W, Shi S, Ying J, Lyu N. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. J Cancer Res Clin Oncol 2018;144:2149-59. [DOI: 10.1007/s00432-018-2742-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, Greil R. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). BMC Cancer 2018;18:11. [PMID: 29298682 DOI: 10.1186/s12885-017-3955-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017;8:3980-4000. [PMID: 28002810 DOI: 10.18632/oncotarget.14012] [Cited by in Crossref: 121] [Cited by in F6Publishing: 115] [Article Influence: 30.3] [Reference Citation Analysis]
47 Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol 2016;70:771-5. [PMID: 27178450 DOI: 10.1016/j.eururo.2016.04.037] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
48 Moradi-kalbolandi S, Hosseinzade A, Salehi M, Merikhian P, Farahmand L. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. Journal of Pharmacy and Pharmacology 2018;70:841-54. [DOI: 10.1111/jphp.12911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
49 Quezada-Marín JI, Lam AK, Ochiai A, Odze RD, Washington KM, Fukayama M, Rugge M, Klimstra DS, Nagtegaal ID, Tan PH, Arends MJ, Goldblum JR, Cree IA, Salto-Tellez M. Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology 2020;77:340-50. [PMID: 32320495 DOI: 10.1111/his.14120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
50 Kerachian MA, Poudineh A, Thiery JP. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. Critical Reviews in Oncology/Hematology 2019;144:102827. [DOI: 10.1016/j.critrevonc.2019.102827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
51 Gong W, Zheng J, Liu X, Ma J, Liu Y, Xue Y. Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e. Oncotarget 2016;7:62208-23. [PMID: 27556696 DOI: 10.18632/oncotarget.11403] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 15.0] [Reference Citation Analysis]
52 Hu Y, Tao SY, Deng JM, Hou ZK, Liang JQ, Huang QG, Li LH, Li HB, Chen YM, Yi H, Chen XL, Liu H. Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018;19:3001-3008. [PMID: 30484984 DOI: 10.31557/apjcp.2018.19.11.3001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
53 Ren Y, Zhao C, He Y, Min X, Xu H, Hu X. RPARP-AS1/miR125a-5p Axis Promotes Cell Proliferation, Migration and Invasion in Colon Cancer. Onco Targets Ther 2021;14:5035-43. [PMID: 34675548 DOI: 10.2147/OTT.S304494] [Reference Citation Analysis]
54 Wong XY, Lim AQJ, Shen Q, Chia JWK, Chew MH, Tan WS, Wee HL. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment. Curr Med Res Opin 2020;36:1677-86. [PMID: 32609014 DOI: 10.1080/03007995.2020.1790348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zaryouh H, De Pauw I, Baysal H, Peeters M, Vermorken JB, Lardon F, Wouters A. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. Med Res Rev 2021. [PMID: 33928670 DOI: 10.1002/med.21806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Kasper S, Reis H, Ziegler S, Nothdurft S, Mueller A, Goetz M, Wiesweg M, Phasue J, Ting S, Wieczorek S, Even A, Worm K, Pogorzelski M, Breitenbuecher S, Meiler J, Paul A, Trarbach T, Schmid KW, Breitenbuecher F, Schuler M. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. Oncotarget 2017;8:45898-917. [PMID: 28507280 DOI: 10.18632/oncotarget.17438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Cheng CC, Liao PN, Ho AS, Lim KH, Chang J, Su YW, Chen CG, Chiang YW, Yang BL, Lin HC, Chang YC, Chang CC, Chang YF. STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening. J Biomed Sci 2018;25:60. [PMID: 30068339 DOI: 10.1186/s12929-018-0456-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
58 Ahadi M, Sokolova A, Brown I, Chou A, Gill AJ. The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. Pathology 2021;53:454-61. [PMID: 33461799 DOI: 10.1016/j.pathol.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Park YL, Kim HP, Ock CY, Min DW, Kang JK, Lim YJ, Song SH, Han SW, Kim TY. EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. Oncogene 2022. [PMID: 35173310 DOI: 10.1038/s41388-021-01920-4] [Reference Citation Analysis]
60 Sanchez-Ibarra HE, Jiang X, Gallegos-Gonzalez EY, Cavazos-González AC, Chen Y, Morcos F, Barrera-Saldaña HA. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study. PLoS One 2020;15:e0235490. [PMID: 32628708 DOI: 10.1371/journal.pone.0235490] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Prentice LM, Miller RR, Knaggs J, Mazloomian A, Aguirre Hernandez R, Franchini P, Parsa K, Tessier-Cloutier B, Lapuk A, Huntsman D, Schaeffer DF, Sheffield BS. Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice. PLoS One 2018;13:e0196434. [PMID: 29698444 DOI: 10.1371/journal.pone.0196434] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
62 Kamashev D, Sorokin M, Kochergina I, Drobyshev A, Vladimirova U, Zolotovskaia M, Vorotnikov I, Shaban N, Raevskiy M, Kuzmin D, Buzdin A. Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. Heliyon 2021;7:e06394. [PMID: 33748471 DOI: 10.1016/j.heliyon.2021.e06394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
63 Wrobel P, Ahmed S. Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis 2019;34:13-25. [PMID: 30465238 DOI: 10.1007/s00384-018-3202-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
64 Nelson AC, Turbyville TJ, Dharmaiah S, Rigby M, Yang R, Wang TY, Columbus J, Stephens R, Taylor T, Sciacca D, Onsongo G, Sarver A, Subramanian S, Nissley DV, Simanshu DK, Lou E. RAS internal tandem duplication disrupts GTPase-activating protein (GAP) binding to activate oncogenic signaling. J Biol Chem 2020;295:9335-48. [PMID: 32393580 DOI: 10.1074/jbc.RA119.011080] [Reference Citation Analysis]
65 Schröder C, Gower-Page C, Reyes-Rivera I, Patel A, Price R, Sen S, Davies J, Castellanos E, Snider J, Bai X, Fisher V, Mhatre SK. Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. JCO Clin Cancer Inform 2022;6:e2100133. [PMID: 35297649 DOI: 10.1200/CCI.21.00133] [Reference Citation Analysis]
66 Xiao N, Tang YT, Li ZS, Cao R, Wang R, Zou JM, Pei J. Performance of probe polymerization-conjunction-agarose gel electrophoresis in the rapid detection of KRAS gene mutation. Genet Mol Biol 2018;41:555-61. [PMID: 30080912 DOI: 10.1590/1678-4685-GMB-2017-0197] [Reference Citation Analysis]
67 Shin W, Lee SK, Hwang JH, Park JC, Cho YH, Ro EJ, Song Y, Seo HR, Choi KY. Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling. Exp Mol Med 2018;50:1-10. [PMID: 29884842 DOI: 10.1038/s12276-018-0102-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
68 Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, Malapelle U, Fassan M. FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. JPM 2022;12:750. [DOI: 10.3390/jpm12050750] [Reference Citation Analysis]
69 Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, Capalbo C, Alesse E, Tessitore A. Next-generation sequencing: recent applications to the analysis of colorectal cancer. J Transl Med. 2017;15:246. [PMID: 29221448 DOI: 10.1186/s12967-017-1353-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
70 Hasbal-Celikok G, Aksoy-Sagirli P, Altiparmak-Ulbegi G, Can A. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. Oncol Lett 2021;21:209. [PMID: 33574948 DOI: 10.3892/ol.2021.12470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Valverde A, Peñarando J, Cañas A, López-Sánchez LM, Conde F, Guil-Luna S, Hernández V, Villar C, Morales-Estévez C, de la Haba-Rodríguez J, Aranda E, Rodríguez-Ariza A. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. Oncotarget 2017;8:21754-69. [PMID: 28423516 DOI: 10.18632/oncotarget.15567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
72 Janakiraman H, Zhu Y, Becker SA, Wang C, Cross A, Curl E, Lewin D, Hoffman BJ, Warren GW, Hill EG, Timmers C, Findlay VJ, Camp ER. Modeling rectal cancer to advance neoadjuvant precision therapy. Int J Cancer 2020;147:1405-18. [PMID: 31989583 DOI: 10.1002/ijc.32876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
73 Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. Bioconjug Chem 2018;29:3817-32. [PMID: 30350574 DOI: 10.1021/acs.bioconjchem.8b00667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]